Apyx Medical Corporation Financials

APYX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Apyx Medical Corporation (APYX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APYX FY2025 2026-05-07

Loss reduction came mainly from expense cuts, while debt-backed liquidity still bridges a business short of cash breakeven.

FY2025 showed a much smaller operating cash burn, improving to -$8.0M from -$18.0M in FY2024. But the cash balance stayed near $31.7M only because financing inflows added $9.6M, which means the better income statement has not yet translated into self-funding operations.

Operating improvement in FY2025 reflects cost discipline more than a stronger unit economics story: revenue reached $52.8M and gross margin only nudged to 62.5%. The bigger change was a roughly $4.8M reduction in SG&A plus R&D versus FY2024, pointing to a leaner expense base rather than a dramatic shift in product profitability.

Balance-sheet posture is split between comfortable short-term liquidity and heavier long-term obligations: the current ratio stayed near 5.0x while debt to equity remained about 2.4x. With interest expense at $5.6M against an operating loss of -$6.4M, financing costs now absorb much of the benefit from the operating turnaround.

Financial Health Signals

Financial Health Score 47/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Apyx Medical Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

1.57

Apyx Medical Corporation scores 1.57, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($184.4M) relative to total liabilities ($52.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Apyx Medical Corporation passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.71x

For every $1 of reported earnings, Apyx Medical Corporation generates $0.71 in operating cash flow (-$8.0M OCF vs -$11.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1.2x

Apyx Medical Corporation earns $-1.2 in operating income for every $1 of interest expense (-$6.4M vs $5.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$52.8M

YoY+9.9%

5Y CAGR+13.8%

10Y CAGR+6.0%

Apyx Medical Corporation generated $52.8M in revenue in fiscal year 2025. This represents an increase of 9.9% from the prior year.

EBITDA

-$5.8M

YoY+68.3%

Apyx Medical Corporation's EBITDA was -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.3% from the prior year.

Net Income

-$11.2M

YoY+52.2%

Apyx Medical Corporation reported -$11.2M in net income in fiscal year 2025. This represents an increase of 52.2% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$9.1M

YoY+51.4%

Apyx Medical Corporation generated -$9.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 51.4% from the prior year.

Cash & Debt

$31.7M

YoY-0.0%

5Y CAGR-5.4%

10Y CAGR+10.4%

Apyx Medical Corporation held $31.7M in cash against $34.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

42M

YoY+10.6%

5Y CAGR+4.0%

10Y CAGR+4.4%

Apyx Medical Corporation had 42M shares outstanding in fiscal year 2025. This represents an increase of 10.6% from the prior year.

Margins & Returns

Gross Margin

62.5%

YoY+1.5pp

5Y CAGR-0.6pp

10Y CAGR+20.0pp

Apyx Medical Corporation's gross margin was 62.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the prior year.

Operating Margin

-12.2%

YoY+27.0pp

5Y CAGR+60.3pp

10Y CAGR+11.5pp

Apyx Medical Corporation's operating margin was -12.2% in fiscal year 2025, reflecting core business profitability. This is up 27.0 percentage points from the prior year.

Net Margin

-21.2%

YoY+27.6pp

5Y CAGR+21.7pp

10Y CAGR-3.0pp

Apyx Medical Corporation's net profit margin was -21.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.6 percentage points from the prior year.

Return on Equity

-77.1%

YoY+88.0pp

5Y CAGR-58.4pp

10Y CAGR-54.2pp

Apyx Medical Corporation's ROE was -77.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 88.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$3.4M

YoY-33.6%

5Y CAGR-3.0%

10Y CAGR+4.6%

Apyx Medical Corporation invested $3.4M in research and development in fiscal year 2025. This represents a decrease of 33.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.1M

YoY+54.3%

5Y CAGR+13.9%

10Y CAGR+10.2%

Apyx Medical Corporation invested $1.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.3% from the prior year.

APYX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$52.8M+9.9%	$48.1M-8.1%	$52.3M+17.6%	$44.5M-8.3%	$48.5M+75.1%	$27.7M
Cost of Revenue	$19.8M+5.6%	$18.7M+0.8%	$18.6M+20.9%	$15.4M+3.1%	$14.9M+46.1%	$10.2M
Gross Profit	$33.0M+12.5%	$29.4M-13.0%	$33.8M+15.9%	$29.1M-13.3%	$33.6M+92.0%	$17.5M
R&D Expenses	$3.4M-33.6%	$5.1M-6.6%	$5.4M+19.7%	$4.5M+5.2%	$4.3M+10.2%	$3.9M
SG&A Expenses	$15.8M-16.2%	$18.9M-15.0%	$22.2M+8.4%	$20.5M+10.0%	$18.6M+59.3%	$11.7M
Operating Income	-$6.4M+65.8%	-$18.8M-9.2%	-$17.3M+26.8%	-$23.6M-63.1%	-$14.4M+28.1%	-$20.1M
Interest Expense	$5.6M-5.4%	$5.9M+138.4%	$2.5M+16420.0%	$15K+50.0%	$10K-78.3%	$46K
Income Tax	$270K+7.1%	$252K+110.4%	-$2.4M-762.7%	$367K-3.4%	$380K+105.1%	-$7.5M
Net Income	-$11.2M+52.2%	-$23.5M-25.4%	-$18.7M+19.3%	-$23.2M-52.8%	-$15.2M-27.5%	-$11.9M
EPS (Diluted)	N/A	N/A	$-0.54+19.4%	$-0.67-52.3%	$-0.44-25.7%	$-0.35

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$12.5M-34.8%	$19.2M+48.8%	$12.9M+13.2%	$11.4M+20.6%	$9.4M-33.7%	$14.2M+23.8%	$11.5M-5.4%	$12.1M
Cost of Revenue	$4.6M-36.3%	$7.2M+56.4%	$4.6M+6.8%	$4.3M+13.9%	$3.8M-28.4%	$5.3M+16.0%	$4.5M-2.6%	$4.7M
Gross Profit	$7.9M-34.0%	$12.0M+44.6%	$8.3M+17.1%	$7.1M+25.0%	$5.7M-36.8%	$9.0M+28.9%	$7.0M-7.2%	$7.5M
R&D Expenses	$765K-19.0%	$944K+17.9%	$801K-2.8%	$824K+2.5%	$804K-28.0%	$1.1M-2.2%	$1.1M-19.8%	$1.4M
SG&A Expenses	$3.6M-21.3%	$4.5M+24.2%	$3.7M-11.7%	$4.1M+19.4%	$3.5M-28.3%	$4.8M+12.6%	$4.3M-11.3%	$4.8M
Operating Income	-$911K-8381.8%	$11K+101.3%	-$832K+67.7%	-$2.6M+15.6%	-$3.1M-0.1%	-$3.0M+16.1%	-$3.6M+34.5%	-$5.5M
Interest Expense	$1.4M-2.7%	$1.4M-0.4%	$1.4M+1.4%	$1.4M+1.2%	$1.4M-16.8%	$1.7M+15.5%	$1.4M+0.3%	$1.4M
Income Tax	$143K+52.1%	$94K+20.5%	$78K+59.2%	$49K0.0%	$49K-44.9%	$89K+48.3%	$60K+20.0%	$50K
Net Income	-$2.1M-62.3%	-$1.3M+34.5%	-$2.0M+47.5%	-$3.8M+9.0%	-$4.2M+10.3%	-$4.6M+1.6%	-$4.7M+28.3%	-$6.6M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$-0.19

APYX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$66.8M+3.1%	$64.8M-18.2%	$79.2M+53.0%	$51.8M-24.7%	$68.7M-7.3%	$74.1M
Current Assets	$58.5M+3.6%	$56.4M-19.8%	$70.4M+63.7%	$43.0M-29.2%	$60.7M-8.1%	$66.1M
Cash & Equivalents	$31.7M0.0%	$31.7M-27.3%	$43.7M+328.3%	$10.2M-67.0%	$30.9M-26.4%	$41.9M
Inventory	$8.6M+13.7%	$7.6M-23.8%	$9.9M-15.9%	$11.8M+74.0%	$6.8M+67.3%	$4.1M
Accounts Receivable	$16.8M+8.4%	$15.5M+10.4%	$14.0M+32.3%	$10.6M-18.7%	$13.0M+55.2%	$8.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$52.0M+3.0%	$50.5M-3.5%	$52.3M+274.2%	$14.0M-5.0%	$14.7M+43.5%	$10.3M
Current Liabilities	$11.7M+9.1%	$10.7M-15.8%	$12.7M+7.5%	$11.8M-10.3%	$13.2M+44.3%	$9.2M
Long-Term Debt	$34.8M+2.8%	$33.9M+2.1%	$33.2M	$0	N/A	N/A
Total Equity	$14.5M+2.3%	$14.2M-46.8%	$26.7M-29.0%	$37.6M-30.0%	$53.7M-15.7%	$63.7M
Retained Earnings	-$89.1M-14.4%	-$77.9M-43.1%	-$54.4M-52.4%	-$35.7M-184.7%	-$12.6M-578.9%	$2.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$63.0M-5.7%	$66.8M+16.5%	$57.4M-1.4%	$58.2M-3.3%	$60.2M-7.2%	$64.8M+6.8%	$60.7M-7.1%	$65.4M
Current Assets	$54.8M-6.3%	$58.5M+19.8%	$48.8M-2.3%	$49.9M-3.7%	$51.9M-8.1%	$56.4M+8.2%	$52.2M-8.0%	$56.7M
Cash & Equivalents	$31.1M-1.9%	$31.7M+26.3%	$25.1M-14.2%	$29.3M-5.5%	$31.0M-2.3%	$31.7M+13.3%	$28.0M-14.3%	$32.7M
Inventory	$9.5M+10.9%	$8.6M-5.9%	$9.1M+11.6%	$8.2M+6.6%	$7.7M+1.6%	$7.6M-16.0%	$9.0M-3.5%	$9.3M
Accounts Receivable	$12.8M-24.0%	$16.8M+29.1%	$13.0M+15.5%	$11.2M-3.4%	$11.6M-24.8%	$15.5M+18.7%	$13.0M+2.6%	$12.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$49.9M-4.0%	$52.0M+1.4%	$51.3M+1.1%	$50.7M+2.5%	$49.5M-2.0%	$50.5M+2.0%	$49.5M-1.9%	$50.5M
Current Liabilities	$9.4M-19.3%	$11.7M+6.6%	$11.0M+3.9%	$10.6M+11.1%	$9.5M-11.3%	$10.7M+12.2%	$9.6M-10.2%	$10.6M
Long-Term Debt	$35.1M+0.7%	$34.8M+0.7%	$34.6M+0.7%	$34.4M+0.7%	$34.1M+0.7%	$33.9M+0.1%	$33.9M+0.7%	$33.6M
Total Equity	$12.8M-11.7%	$14.5M+148.6%	$5.8M-19.4%	$7.3M-31.0%	$10.5M-26.0%	$14.2M+28.7%	$11.0M-25.1%	$14.7M
Retained Earnings	-$91.2M-2.4%	-$89.1M-1.5%	-$87.8M-2.3%	-$85.8M-4.6%	-$82.1M-5.3%	-$77.9M-6.3%	-$73.3M-6.9%	-$68.6M

APYX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.0M+55.7%	-$18.0M-243.8%	-$5.2M+74.1%	-$20.3M-94.1%	-$10.4M+35.0%	-$16.1M
Capital Expenditures	$1.1M+54.3%	$722K+35.5%	$533K-47.2%	$1.0M+39.7%	$723K+24.4%	$581K
Free Cash Flow	-$9.1M+51.4%	-$18.8M-224.6%	-$5.8M+72.8%	-$21.3M-90.6%	-$11.2M+32.9%	-$16.6M
Investing Cash Flow	-$1.1M-54.3%	-$722K-110.7%	$6.7M+766.7%	-$1.0M-39.7%	-$723K-24.4%	-$581K
Financing Cash Flow	$9.6M+42.0%	$6.7M-79.0%	$32.2M+14723.0%	$217K+804.2%	$24K+132.9%	-$73K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$572K+77.4%	-$2.5M+28.5%	-$3.5M-186.8%	-$1.2M-75.6%	-$702K+76.1%	-$2.9M+33.9%	-$4.4M-2.6%	-$4.3M
Capital Expenditures	$60K-78.2%	$275K-47.0%	$519K+95.8%	$265K+381.8%	$55K-77.6%	$245K+60.1%	$153K-47.1%	$289K
Free Cash Flow	-$632K+77.5%	-$2.8M+30.8%	-$4.1M-170.7%	-$1.5M-97.9%	-$757K+76.2%	-$3.2M+30.7%	-$4.6M+0.5%	-$4.6M
Investing Cash Flow	-$60K+78.2%	-$275K+47.0%	-$519K-95.8%	-$265K-381.8%	-$55K+77.6%	-$245K-60.1%	-$153K+47.1%	-$289K
Financing Cash Flow	$83K-99.1%	$9.5M+20977.8%	$45K+80.0%	$25K0.0%	$25K-99.6%	$6.8M+135300.0%	-$5K0.0%	-$5K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APYX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	62.5%+1.5pp	61.0%-3.4pp	64.5%-1.0pp	65.5%-3.8pp	69.3%+6.1pp	63.2%
Operating Margin	-12.2%+27.0pp	-39.2%-6.2pp	-33.0%+20.0pp	-52.9%-23.2pp	-29.8%+42.7pp	-72.5%
Net Margin	-21.2%+27.6pp	-48.8%-13.0pp	-35.8%+16.3pp	-52.1%-20.8pp	-31.3%+11.7pp	-42.9%
Return on Equity	-77.1%+88.0pp	-165.1%-95.0pp	-70.1%-8.4pp	-61.7%-33.4pp	-28.2%-9.6pp	-18.7%
Return on Assets	-16.8%+19.4pp	-36.2%-12.6pp	-23.6%+21.2pp	-44.8%-22.7pp	-22.1%-6.0pp	-16.1%
Current Ratio	5.00-0.3	5.26-0.3	5.52+1.9	3.63-1.0	4.60-2.6	7.22
Debt-to-Equity	2.40+0.0	2.39+1.1	1.24+1.2	0.00-0.3	0.27+0.1	0.16
FCF Margin	-17.3%+21.8pp	-39.0%-28.0pp	-11.1%+36.8pp	-47.8%-24.8pp	-23.0%+37.0pp	-60.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	63.4%+0.8pp	62.6%-1.8pp	64.4%+2.1pp	62.3%+2.2pp	60.1%-3.0pp	63.0%+2.5pp	60.5%-1.1pp	61.7%
Operating Margin	-7.3%-7.4pp	0.1%+6.5pp	-6.5%+16.2pp	-22.6%+9.7pp	-32.4%-10.9pp	-21.4%+10.2pp	-31.6%+14.0pp	-45.7%
Net Margin	-16.9%-10.1pp	-6.8%+8.6pp	-15.4%+17.8pp	-33.2%+10.8pp	-44.0%-11.5pp	-32.5%+8.4pp	-40.9%+13.0pp	-54.0%
Return on Equity	-16.4%-7.5pp	-8.9%+25.0pp	-33.9%+18.2pp	-52.1%-12.6pp	-39.5%-6.9pp	-32.6%+10.0pp	-42.6%+1.9pp	-44.5%
Return on Assets	-3.3%-1.4pp	-1.9%+1.5pp	-3.5%+3.0pp	-6.5%+0.4pp	-6.9%+0.2pp	-7.1%+0.6pp	-7.8%+2.3pp	-10.0%
Current Ratio	5.80+0.8	5.00+0.6	4.44-0.3	4.72-0.7	5.45+0.2	5.26-0.2	5.46+0.1	5.33
Debt-to-Equity	2.73+0.3	2.40-3.5	5.92+1.2	4.74+1.5	3.25+0.9	2.39-0.7	3.07+0.8	2.28
FCF Margin	-5.1%+9.6pp	-14.6%+16.9pp	-31.5%-18.3pp	-13.2%-5.1pp	-8.0%+14.3pp	-22.4%+17.6pp	-40.0%-2.0pp	-38.0%

Similar Companies

Xtant Medical XTNT

$58.9M

Pulmonx Corp LUNG

$65.0M

Baird Medical BDMD

$36.1M

IceCure Medical Ltd. ICCM

$12.5M

Tela Bio, Inc. TELA

$37.9M

Frequently Asked Questions

What is Apyx Medical Corporation's annual revenue?

Apyx Medical Corporation (APYX) reported $52.8M in total revenue for fiscal year 2025. This represents a 9.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Apyx Medical Corporation's revenue growing?

Apyx Medical Corporation (APYX) revenue grew by 9.9% year-over-year, from $48.1M to $52.8M in fiscal year 2025.

Is Apyx Medical Corporation profitable?

No, Apyx Medical Corporation (APYX) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -21.2%.

What is Apyx Medical Corporation's EBITDA?

Apyx Medical Corporation (APYX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Apyx Medical Corporation have?

As of fiscal year 2025, Apyx Medical Corporation (APYX) had $31.7M in cash and equivalents against $34.8M in long-term debt.

What is Apyx Medical Corporation's gross margin?

Apyx Medical Corporation (APYX) had a gross margin of 62.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Apyx Medical Corporation's operating margin?

Apyx Medical Corporation (APYX) had an operating margin of -12.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Apyx Medical Corporation's net profit margin?

Apyx Medical Corporation (APYX) had a net profit margin of -21.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Apyx Medical Corporation's return on equity (ROE)?

Apyx Medical Corporation (APYX) has a return on equity of -77.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Apyx Medical Corporation's free cash flow?

Apyx Medical Corporation (APYX) generated -$9.1M in free cash flow during fiscal year 2025. This represents a 51.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Apyx Medical Corporation's operating cash flow?

Apyx Medical Corporation (APYX) generated -$8.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Apyx Medical Corporation's total assets?

Apyx Medical Corporation (APYX) had $66.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Apyx Medical Corporation's capital expenditures?

Apyx Medical Corporation (APYX) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Apyx Medical Corporation spend on research and development?

Apyx Medical Corporation (APYX) invested $3.4M in research and development during fiscal year 2025.

How many shares does Apyx Medical Corporation have outstanding?

Apyx Medical Corporation (APYX) had 42M shares outstanding as of fiscal year 2025.

What is Apyx Medical Corporation's current ratio?

Apyx Medical Corporation (APYX) had a current ratio of 5.00 as of fiscal year 2025, which is generally considered healthy.

What is Apyx Medical Corporation's debt-to-equity ratio?

Apyx Medical Corporation (APYX) had a debt-to-equity ratio of 2.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Apyx Medical Corporation's return on assets (ROA)?

Apyx Medical Corporation (APYX) had a return on assets of -16.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Apyx Medical Corporation's cash runway?

Based on fiscal year 2025 data, Apyx Medical Corporation (APYX) had $31.7M in cash against an annual operating cash burn of $8.0M. This gives an estimated cash runway of approximately 48 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Apyx Medical Corporation's Altman Z-Score?

Apyx Medical Corporation (APYX) has an Altman Z-Score of 1.57, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Apyx Medical Corporation's Piotroski F-Score?

Apyx Medical Corporation (APYX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Apyx Medical Corporation's earnings high quality?

Apyx Medical Corporation (APYX) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Apyx Medical Corporation cover its interest payments?

Apyx Medical Corporation (APYX) has an interest coverage ratio of -1.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Apyx Medical Corporation?

Apyx Medical Corporation (APYX) scores 47 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.